Quote this publication Share Print

AURICULARUM (oxytetracycline, polymyxin B, dexamethasone, nystatin), anti-infective and corticosteroid in combination

ENT - Update
Opinions on drugs - Posted on Jun 27 2018

Reason for request

Re-assessment of the actual benefit

Low clinical benefit in the topical treatment of chronic otitis for perioperative use

  •  AURICULARUM has been granted a marketing authorisation for the topical treatment of chronic otitis: for pre-operative draining and for post-operative use in the petromastoid canal, with or without tympanoplasty.
  • Fluoroquinolone ear drops are the first-line treatments of chronic otitis. The role of AURICULARUM, containing an antifungal agent combined with two non-fluoroquinolone antibiotics, is limited in the therapeutic strategy for otitis externa; it should be reserved for cases of acute otitis externa of fungal or combined fungal and bacterial origin. 

 

 


Actual benefit

Faible

-